SCHEMBL2129095

SCHEMBL2129095

COc1cc(Cl)c(C(=O)O)cc1Br

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 1/20 0.58
FYN P06241 1/20 0.58
ALDH1A1 P00352 8/20 0.46
KDM4E B2RXH2 4/20 0.46
HPGD P15428 3/20 0.46
HSD17B10 Q99714 2/20 0.46
TP53 P04637 1/20 0.44
MRGPRX4 Q96LA9 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
HTT P42858 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
KCNH2 Q12809 1/20 0.43
MAPT P10636 2/20 0.42
GFER P55789 1/20 0.42
CLCN2 P51788 1/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15795417 0.93 LCK (0.62) LCKFYNALDH1A1KDM4EHPGD
SCHEMBL10712499 0.87 LCK (0.59) LCKFYNALDH1A1KDM4EHPGD
SCHEMBL31096338 0.87 LCK (0.59) LCKFYNALDH1A1KDM4EHPGD
SCHEMBL30356409 0.86 HTT (0.46) LCKFYNALDH1A1HPGDHTT
SCHEMBL29025712 0.86 HTT (0.46) LCKFYNALDH1A1HPGDHTT
Hydrochloric Acid SCHEMBL10980399 0.86 LCK (0.58) LCKFYNALDH1A1KDM4EHPGD
SCHEMBL25339845 0.85 LCK (0.71) LCKFYNALDH1A1KDM4EHPGD
SCHEMBL1918763 0.85 LCK (0.66) LCKFYNALDH1A1KDM4EHPGD
SCHEMBL30448157 0.85 LCK (0.71) LCKFYNALDH1A1KDM4EHPGD
SCHEMBL2818164 0.85 LCK (0.60) LCKFYNALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2714032-B1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORP (KR) 2019-01-16 EP disclosed
US-9371303-B2 Diphenylmethane derivatives as SGLT2 inhibitors GREEN CROSS CORPORATION (KR) 2016-06-21 US disclosed
US-20150152075-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2015-06-04 US disclosed
US-9034921-B2 Diphenylmethane derivatives as SGLT2 inhibitors GREEN CROSS CORPORATION (KR) 2015-05-19 US disclosed
US-8921412-B2 C-aryl ansa SGLT2 inhibitors GREEN CROSS CORPORATION (KR) 2014-12-30 US disclosed
US-8921412-B2 C-aryl ansa SGLT2 inhibitors GREEN CROSS CORPORATION (KR) 2014-12-30 US disclosed
US-8921412-B2 C-aryl ansa SGLT2 inhibitors GREEN CROSS CORPORATION (KR) 2014-12-30 US disclosed
US-20140213642-A1 NOVEL C-ARYL ANSA SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2014-07-31 US disclosed
US-20140213642-A1 NOVEL C-ARYL ANSA SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2014-07-31 US disclosed
US-20140213642-A1 NOVEL C-ARYL ANSA SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2014-07-31 US disclosed
US-20130090298-A1 Thiazole Derivatives as SGLT2 Inhibitors and Pharmaceutical Composition Comprising Same GREEN CROSS CORPORATION (KR) 2013-04-11 US disclosed
WO-2012173410-A2 NOVEL C-ARYL ANSA SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2012-12-20 WO disclosed
WO-2012173410-A2 NOVEL C-ARYL ANSA SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2012-12-20 WO disclosed
WO-2012165914-A2 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2012-12-06 WO disclosed
US-20120101051-A1 NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME GREEN CROSS CORPORATION (KR) 2012-04-26 US disclosed
US-20120101051-A1 NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME GREEN CROSS CORPORATION (KR) 2012-04-26 US disclosed
WO-2011159067-A2 THIAZOLE DERIVATIVES AS SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2011-12-22 WO disclosed
WO-2011159067-A2 THIAZOLE DERIVATIVES AS SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2011-12-22 WO disclosed
WO-2010147430-A2 NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2010-12-23 WO disclosed
WO-2010147430-A2 NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130090298-A1 Thiazole Derivatives as SGLT2 Inhibitors and Pharmaceutical Composition Comprising Same SLC5A2, SLC5A1, SLC10A2 LCK 1362/4885FYN 2663/4885ALDH1A1 1292/4885
US-20120101051-A1 NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME SLC5A2, SLC5A1, SLC2A2 LCK 1747/4885FYN 2400/4885ALDH1A1 1785/4885
US-20140213642-A1 NOVEL C-ARYL ANSA SGLT2 INHIBITORS SLC5A2, SLC5A1, SLC2A1 LCK 4119/4885FYN 3925/4885ALDH1A1 550/4885
US-20150152075-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS SLC5A2, SLC5A1, SLC2A8 LCK 1774/4885FYN 3412/4885ALDH1A1 1076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.